There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > LILRB2


LILRB2 Molecule Information

Name:Leukocyte immunoglobulin-like receptor subfamily B member 2
Target Synonym:Myeloid Inhibitory Receptor 10?CD85d Antigen?ILT4?LIR2?CD85d?LIR-2?Leukocyte immunoglobulin-like receptor 2?CD85 antigen-like family member D?Immunoglobulin-like transcript 4?ILT-4?Monocyte/macrophage immunoglobulin-like receptor 10?MIR-10?CD_antigen: CD8
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:1
Lastest Research Phase:Phase 2 Clinical

LILRB2 Protein Product ListCompare or Buy

By Product Status:
By Product Category:
By Species:
Cat. No. Species Product Description Structure Purity Feature
LI2-H82F5 Human Biotinylated Human LILRB2 / CD85d / ILT4 Protein, Fc,Avitag™
CDD-H5259 Human Human LILRB2 / CD85d / ILT4 Protein, Fc tag
LI2-H5220 Human Human LILRB2 / CD85d / ILT4 Protein, His Tag

LILRB2 Molecule Synonym Name


LILRB2 Molecule Background

Leukocyte immunoglobulin-like receptor subfamily B member 2 (LILRB2) is also known as CD85 antigen-like family member D (CD85d), Immunoglobulin-like transcript 4 (ILT-4), Monocyte / macrophage immunoglobulin-like receptor 10 (MIR-10), which is a member of the the subfamily B class of LIR receptors. LILRB2 is receptor for class I MHC antigens. LILRB2 recognizes a broad spectrum of HLA-A, HLA-B, HLA-C and HLA-G alleles. LILRB2 competes with CD8A for binding to class I MHC antigens. LILRB2 / CD85d inhibits FCGR1A-mediated phosphorylation of cellular proteins and mobilization of intracellular calcium ions.

LILRB2 References

LILRB2 Related Molecule

LILRB2 Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
MK-4830 MK-4830 Phase 2 Clinical Merck Sharp & Dohme Corp Carcinoma, Renal Cell; Carcinoma, Non-Small-Cell Lung Details
JTX-8064 JTX-8064 Phase 1 Clinical Jounce Therapeutics Neoplasms Details

This web search service is supported by Google Inc.